Robert MacLeod
Company: ADARx
Job title: Chief Scientific Officer
Seminars:
ADX-038, a Long-Acting CFB siRNA Therapeutic for Multiple Complement Mediated Diseases 3:00 pm
Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficient Delving into the strategic decisions for Factor B when used in addition to expensive C5 inhibitors Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficientRead more
day: End of Day Two